MEGHAN FREEZE: Open Payments
NPI 1205228301 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,078 in 68 payments from 11 companies in 2025. Trend: 2023 $496 · 2024 $1,509 · 2025 $1,078
Food & beverage: $1,058Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $159 |
| Janssen Biotech, Inc. | 10 | $156 |
| Gilead Sciences, Inc. | 4 | $93 |
| Phathom Pharmaceuticals, Inc. | 7 | $76 |
| Ipsen Biopharmaceuticals, Inc | 3 | $73 |
| Madrigal Pharmaceuticals | 3 | $65 |
| Lilly USA, LLC | 2 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: RINVOQ, TREMFYA, ENTYVIO, VOQUEZNA, IQIRVO, REZDIFFRA, OMVOH, CREON.
Industry payments across NE — which companies pay providers there.
